Jikei University School of Medicine

www.jikei.ac.jp/univ/
Tokyo, Japan

The Jikei University School of Medicine is a private university in Minato, Tokyo, Japan. Jikei means mercy and love in Japanese. Wikipedia.


Time filter

Source Type

News Article | May 24, 2017
Site: www.businesswire.com

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) announced the first implants in Japan of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE). Gore has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare to market the IBE and is currently in discussion regarding reimbursement for this region. The IBE is the first off-the-shelf iliac branch solution approved in Japan and the only device indicated for the endovascular treatment of common iliac artery aneursyms or aortoiliac aneursyms. With more than 2,500 commercial implants worldwide, the device is a complete, fully engineered system (Gore designed iliac branch and internal iliac components), which received CE Mark in 2013, registration in Australia and New Zealand in 2015, and FDA and Health Canada approval in 2016. Used in conjunction with the GORE® EXCLUDER® AAA Endoprosthesis, the IBE preserves blood flow in the external and internal iliac arteries. The IBE leverages the design and experience acquired from more than 20 years and 285,000 patients treated* with the GORE EXCLUDER AAA Endoprosthesis and utilizes the same durable, expanded polytetrafluoroethylene (ePTFE) graft and nitinol stent material. The IBE offers an All-in-One System with improved outcomes for the treatment of iliac artery aneurysms while preserving flow to the iliac arteries. Preservation of blood flow in the internal iliac arteries is found to avoid pelvic flow disruption and reduce the rate of complications that can include buttock claudication, sexual dysfunction, and colonic ischemia. “Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR,” said Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed the first two implants in Japan. “In many patients, it is imperative that iliac artery blood flow be maintained when possible to avoid complications that can result when these arteries are sacrificed. The IBE will not only reduce complications but also expand the indication for less invasive endovascular treatment for patients that were rejected due to the inability to preserve internal iliac arteries. This is excellent news for Japanese patients.” The IBE system provides a treatment range of 6.5-13.5 mm for the internal iliac arteries, and a treatment range of 6.5-25 mm for the external iliac arteries. The delivery profile of the loaded catheter allows the use of a 16 Fr introducer sheath for the iliac branch component, and a flexible 12 Fr, reinforced introducer sheath for the internal iliac component. “We are pleased to receive approval of this device in regions worldwide as it continues to provide an iliac branch solution for a patient group with a previously unmet treatment need,” said Eric Zacharias, Vascular Business Leader. “Together with physicians, we have spent the past 20 years determining patient needs and continually working to improve our aortic family of devices to provide solutions physicians trust and patients count on. The IBE is an exciting innovation that stems from our mission to effectively treat aortic aneurysms through minimally invasive means.” * Based on the number of Trunk-Ipsilateral Leg components distributed. Gore Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. www.goremedical.com W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments — from revolutionizing the outerwear industry with GORE-TEX® fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and continued recognition from the Great Place to Work® Institute. Headquartered in Newark, Del., Gore employs approximately 10,000 Associates and generates annual revenues that exceed $3 billion. www.gore.com Products listed may not be available in all markets. GORE®, EXCLUDER®, and designs are trademarks of W. L. Gore & Associates. AWO584-EN1 MAY 2017


Araya J.,Jikei University School of Medicine | Nishimura S.L.,University of California at San Francisco
Annual Review of Pathology: Mechanisms of Disease | Year: 2010

Fibrogenic lung reactions occur as a common phenotype shared among disorders of heterogeneous etiologies. Even with a common etiology, the extent and pattern of fibrosis vary greatly among individuals, even within families, suggesting complex gene-environment interactions. The search for mechanisms shared among all fibrotic lung diseases would represent a major advance in the identification of therapeutic targets that could have a broad impact on lung health. Although it is difficult to grasp all of the complexities of the varied cell types and cytokine networks involved in lung fibrogenic responses, and to predict the biologic responses to the overexpression or deficiency of individual cytokines, a large body of evidence converges on a single common theme: the central importance of the transforming growth factor beta (TGF-?) pathway. Therapies that act upstream or downstream of TGF-? activation have the therapeutic potential to treat all fibrogenic responses in the lung. Copyright © 2010 by Annual Reviews.


Patent
Tokyo Women's Medical University, Jikei University School of Medicine and CellSeed | Date: 2013-07-24

The purpose of the present invention is to obtain an alternative to a substitute of the mucosa in the middle ear which is engrafted on the surface of the bone in the middle ear, hyperplasia of the granulation tissue and the bone and the development of the fibroblast cells in the middle ear are suppressed, and to obtain a middle ear mucosa-like cell sheet retaining cilia in the surface layer, comprising culturing nasal epithelium cells on a cell culture substrate coated with a polymer whose hydration force changes within a temperature range of 0 to 80C, wherein the cells are cultured within a temperature range where the hydration force of the polymer is weak, and then changing the temperature to a temperature at which the hydration force is strong to recover the cultured cell sheet.


Patent
Tokyo Women's Medical University, Jikei University School of Medicine and CellSeed | Date: 2016-04-14

The purpose of the present invention is to obtain an alternative to a substitute of the mucosa in the middle ear which is engrafted on the surface of the bone in the middle ear, hyperplasia of the granulation tissue and the bone and the development of the fibroblast cells in the middle ear are suppressed, and to obtain a middle ear mucosa-like cell sheet retaining cilia in the surface layer, comprising culturing nasal epithelium cells on a cell culture substrate coated with a polymer whose hydration force changes within a temperature range of 0 to 80 C., wherein the cells are cultured within a temperature range where the hydration force of the polymer is weak, and then changing the temperature to a temperature at which the hydration force is strong to recover the cultured cell sheet.


Patent
Otsuka Pharmaceutical Factory Inc., Jichi Medical University, Jikei University School of Medicine and Tokyo Women's Medical University | Date: 2014-12-09

The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.


Yokoyama M.,Jikei University School of Medicine
Journal of Drug Targeting | Year: 2014

In this review, polymeric micelles as drug-targeting carriers are concisely explained. In the first introduction part, I describe a brief history of polymer micelle's research for drug targeting, and then I explain this review's focus. Since most other review articles concerning polymeric micelle carriers explain only what was achieved in the polymeric micelle's research, I describe this review by focusing on what was not done. In the second part, I take up three characteristics of polymeric micelle carriers by comparing their advantages and disadvantages, what was done and what was not done in the past studies, and what is easily achieved and what is difficult to be achieved with polymeric micelles. In the last part, I discuss three common problems of nano-sized drug carrier systems including polymeric micelles, and then I add a few comments on these problems. © 2014 Informa UK Ltd.


Patent
Jikei University School of Medicine and Dowa Holdings Co. | Date: 2014-05-19

There is provided an aggregate of radioactive material removing particles in which two or more radioactive material removing particles having magnetic particles and a radioactive material adsorption component are assembled, wherein a pore volume in the aggregate is 0.5 mL/g or more and 5.0 mL/g or less, and the pore volume means a cumulative value obtained by a mercury press-in method.


Patent
Jikei University School of Medicine and Dowa Holdings Co. | Date: 2015-07-15

There is provided a method of producing a radioactive cesium decontaminator, including: suspending magnetic particles in a solvent, and coating each magnetic particle with organic monomer or polymer, to thereby form a precursor; adding a ferrocyanide aqueous solution and an aqueous solution containing at least one kind of transition metal into a suspension liquid containing the precursor after coating while applying a strong shear force, to thereby generate a radioactive cesium decontaminator; and removing water content from a slurry containing the obtained radioactive cesium decontaminator.


Provided is a radioactive substance collecting system and a radioactive substance collecting method which are capable of collecting radioactive substances with high efficiency. The radioactive substance collecting system according to the present invention removes radioactive substances (radioactive cesium 21) contained in a liquid (radioactive substancescontaminated water 20) and includes, as means for removing radioactive substances from the liquid, a radioactive substance trapping composite 1 including at least a magnetic particle 10 and a radioactive substance trapping compound 11 that traps radioactive substances, and magnetic accumulation means 30 for accumulating the radioactive substance trapping composite 1.


Patent
Japanese Foundation For Cancer Research and Jikei University School of Medicine | Date: 2014-06-30

A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Loading Jikei University School of Medicine collaborators
Loading Jikei University School of Medicine collaborators